GE Healthcare and M+W Group form biopharmaceuticals pact
To help emerging nations develop their own manufacturing capabilities for biopharmaceuticals
GE Healthcare and M+W Group, a German engineering, construction and project management company, are to pool GE Healthcare’s expertise in technologies for biopharmaceutical manufacture with M+W Group’s global capabilities in bio-engineering and construction.
The aim is to assist emerging countries worldwide to become self-sufficient in the manufacture of biopharmaceuticals including vaccines, insulin and biosimilars.
Through the initiative, the firms will offer governments and pharmaceutical companies an integrated and cost-effective turnkey approach to constructing biopharmaceutical manufacturing plants.
The alliance aligns with GE’s healthymagination initiative, which focuses on reducing cost, increasing access and improving quality in healthcare.
Olivier Loeillot, general manager of Enterprise Solutions, GE Healthcare Life Sciences, said: ‘By working together to bring an integrated offering – from financing and construction of the plant, right through to training of the operational staff – we can make it much easier for governments to set up their own facilities.’
Dr Tobias Lücke, managing director of M+W Process Industries, and a specialist in Life Science solutions, added: ‘Combining the experience and know-how of our respective companies will bring a new turnkey approach to the much needed local manufacture of potentially life-saving medicines and vaccines.’
